Levi & Korsinsky is investigating Oncolytics Biotech Inc. (“Oncolytics”
or the “Company”) (NasdaqCM: ONCY) for possible violations of federal
securities laws. The investigation stems from the Company’s positive
statements regarding its clinical trial for cancer drug Reolysin.
Click here to learn more about the investigation: http://zlk.9nl.com/oncolytics-biotech-oncy/
or call: 877-363-5972. There is no cost or obligation to you.
On November 21, 2013 Oncolytics issued a press release touting the
“positive top-line data” of its Reolysin trial. The Company’s original
goal was to measure survival, however in its report the Company reported
the results of only 88 of the 118 patients in the trial, claiming others
had received drugs that might bias overall survival results. An article
on thestreet.com published the same day alleges that the Company’s CEO,
Brad Thompson, is “shading the truth” in this report, citing nine “red
flags” that cast doubt on the efficacy of the drug and the validity of
the positive statements made.
If you own Oncolytics stock and wish to obtain additional information
about the investigation and your legal rights, please contact Joseph E.
Levi, Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/oncolytics-biotech-oncy/.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard
Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel:
(212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
www.zlk.com
Copyright Business Wire 2013